Literature DB >> 7828275

Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals.

G N Rudd1, J A Hartley, R L Souhami.   

Abstract

DNA interstrand crosslinks (ISCL) produced by the incubation of human peripheral blood mononuclear cells (PBMs) with cisplatin (CDDP) were measured in two populations of volunteers, one aged less than 25 years and the other, greater than 72 years. The technique of fluorometric alkaline elution was used to measure DNA interstrand crosslinking with time after a 1-h exposure to drug. The samples from the young group showed a more consistent pattern of crosslink formation and removal, with extensive, or in some cases complete, repair at 48 h. Those from the elderly group showed considerable inter-individual variation and significantly higher mean levels of crosslinking at 24 and 48 h. No samples showed complete repair at 48 h in this population. These results indicate an impaired DNA repair capacity in the cells from the elderly group. This may be a factor in the poor tolerance of chemotherapy in the ageing population.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7828275     DOI: 10.1007/BF00689452

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.

Authors:  P Bedford; A M Fichtinger-Schepman; S A Shellard; M C Walker; J R Masters; B T Hill
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

2.  The role of DNA repair in the recovery of human cells from cisplatin toxicity.

Authors:  M F Pera; C J Rawlings; J J Roberts
Journal:  Chem Biol Interact       Date:  1981-10       Impact factor: 5.192

3.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

Authors:  E Reed; R F Ozols; R Tarone; S H Yuspa; M C Poirier
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

4.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.

Authors:  A Eastman
Journal:  Biochemistry       Date:  1986-07-01       Impact factor: 3.162

5.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

Authors:  A M Fichtinger-Schepman; A T van Oosterom; P H Lohman; F Berends
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

6.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

Review 7.  High-dose cisplatin therapy in ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1985-12       Impact factor: 4.929

8.  Peripheral sensory neuropathy and cisplatin chemotherapy.

Authors:  R I Roelofs; W Hrushesky; J Rogin; L Rosenberg
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 9.  Cancer and age.

Authors:  G R Newell; M R Spitz; J G Sider
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

10.  The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.

Authors:  A C Plooy; A M Fichtinger-Schepman; H H Schutte; M van Dijk; P H Lohman
Journal:  Carcinogenesis       Date:  1985-04       Impact factor: 4.944

View more
  12 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective.

Authors:  Vahideh Oveissi; Mahboobe Ram; Roodabeh Bahramsoltani; Farnaz Ebrahimi; Roja Rahimi; Rozita Naseri; Tarun Belwal; Hari Prasad Devkota; Zahra Abbasabadi; Mohammad Hosein Farzaei
Journal:  Daru       Date:  2019-03-09       Impact factor: 3.117

3.  Superhelical torsion controls DNA interstrand cross-linking by antitumor cis- diamminedichloroplatinum(II).

Authors:  O Vrána; V Boudný; V Brabec
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

4.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

5.  Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.

Authors:  Arlene L Oei; Caspar M van Leeuwen; Vidhula R Ahire; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; H Petra Kok; Przemek M Krawczyk; Roland Kanaar; Nicolaas A P Franken
Journal:  Oncotarget       Date:  2017-04-25

6.  The SOS and RpoS Regulons Contribute to Bacterial Cell Robustness to Genotoxic Stress by Synergistically Regulating DNA Polymerase Pol II.

Authors:  Tanja Dapa; Sébastien Fleurier; Marie-Florence Bredeche; Ivan Matic
Journal:  Genetics       Date:  2017-05-03       Impact factor: 4.562

7.  Sensitizing thermochemotherapy with a PARP1-inhibitor.

Authors:  Arlene L Oei; Lianne E M Vriend; Caspar M van Leeuwen; Hans M Rodermond; Rosemarie Ten Cate; Anneke M Westermann; Lukas J A Stalpers; Johannes Crezee; Roland Kanaar; H Petra Kok; Przemek M Krawczyk; Nicolaas A P Franken
Journal:  Oncotarget       Date:  2017-03-07

8.  Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines.

Authors:  Ryan Panchal
Journal:  Ecancermedicalscience       Date:  2017-09-04

9.  Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.

Authors:  Benjamin K Schneider; Arnaud Boyer; Joseph Ciccolini; Fabrice Barlesi; Kenneth Wang; Sebastien Benzekry; Jonathan P Mochel
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-05-09

10.  Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy.

Authors:  P Wynne; C Newton; J A Ledermann; A Olaitan; T A Mould; J A Hartley
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.